Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boston Scientific Advances First ‘Modular’ Cardiac Rhythm Management System

Executive Summary

The MODULAR ATP clinical trial has begun to enroll patients to evaluate the safety, performance and effectiveness of Boston Scientific’s mCRM modular therapy system, which includes the Emblem MRI S-ICD and the Empower MPS leadless pacemaker.

You may also be interested in...



Cardiovascular Catch-Up: Abbott Launches Trial Of Dual-Chamber Leadless Pacer; Cardialen Studies Low-Energy Arrhythmia Treatment; And More

Medtech Insight’s Cardiovascular Catch-Up highlights recent news and insights from cardiovascular device companies – big and small – that you might have missed.

HRS 2020: Boston Scientific’s Emblem S-ICD Proves Safe And Effective In ‘Sickest Population’

Results of two studies presented at the Heart Rhythm Society Scientific Sessions support the subcutaneous implantable cardioverter defibrillator as an alternative to ICDs with transvenous leads.

HRS 2017: Medtronic And Boston Scientific's Less-Invasive CRM Devices Perform As Hoped In Real-World Registries

Results from the post-approval trials of Medtronic's Micra Transcatheter Pacing System and Boston Scientific's S-ICD presented at the Heart Rhythm Society Scientific Sessions in Chicago show these "leadless" devices can be implanted in "real world" patients with acute outcomes similar to those of the pre-market trials that had more restrictive inclusion criteria.

Topics

Related Companies

UsernamePublicRestriction

Register

MT144810

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel